This study developed and validated a high-throughput human papillomavirus (HPV) serology method based on Luminex technology, using pseudovirions (PsVs) of eight mucosal HPV types and two cutaneous HPV types bound to heparin-coated beads. Analysis with neutralizing type-specific monoclonal antibodies against the included HPV types indicated the type specificity of the assay. Analysis of negativecontrol serum samples from 63 children and 71 middle-aged women with up to one lifetime sexual partner indicated high specificity. Positive-control serum samples from subjects with known HPV DNA status or clinical diagnosis found expected sensitivities for most of the HPV types in 219 European serum samples, but lower than expected in 124 samples from Africa. HPV-45 and -52 did not react as expected with the human serum samples. The PsV-Luminex method was used to determine the HPV-seropositivity-associated relative risk for future cervical cancer using 208 serum samples from a prospective study of 18 814 women followed for 23 years, analysed previously with standard HPV-16 ELISA. The PsV-Luminex method gave similar results to ELISA (k50.77). As expected, HPV seropositivities assayed using the PsV-Luminex method found an increased risk of cervical cancer for HPV-16 [odds ratio (OR)57.7, 95 % confidence interval (CI)52.6-23] and HPV-31 (OR54.1, 95 % CI51.6-10.8), non-significant tendencies for increased risk for other mucosal HPV types and no risk for the cutaneous HPV types. In summary, multiplexed HPV serology using mammalian-derived PsVs selected for native conformation by binding to heparin-coated beads was validated as a high-throughput HPV serological method for most of the analysed HPV types.
INTRODUCTION
Genital human papillomavirus (HPV) infections are the most common viral sexually transmitted diseases worldwide and are the main aetiological factors in cervical cancer development (Schiffman et al., 1993; Walboomers et al., 1999) . HPV serology is important in HPV vaccinology and for analysis of past and present HPV infections, as persisting serum antibodies to the major capsid L1 protein develop in the majority of infected subjects (Wang et al., 1996) . Most HPV infections are cleared spontaneously, but among a small subset of infected individuals HPV persists and can cause malignancies (Schiffman et al., 1993) . Because most HPV infections clear within 2 years, current infections detected by DNA analysis are only a minor part of all HPV exposures (Ho et al., 1995) . HPV serology is also a valuable tool to study immune status prior to and after HPV vaccination (Harper et al., 2004; Koutsky et al., 2002) , as antibodies against HPV virus-like particles (VLPs) mediate protective immunity, at least in animalmodel systems (Arbyn & Dillner, 2007) .
HPV VLPs are formed spontaneously after overexpressing the L1 protein in variety of expression systems (Hagensee et al., 1993; Kirnbauer et al., 1992; Le Cann et al., 1994; Sasagawa et al., 1995) . Production of VLPs is demanding, and stability, yield and correct conformation are common issues. HPV pseudovirions (PsVs) produced in mammalian cells are easily made in large amounts and have demonstrated good stability, infectivity and conformational stability (Buck et al., , 2005 Pastrana et al., 2004) . These PsVs contain both L1 and the minor capsid protein L2, and a reporter plasmid can be included as pseudogenome. Codon-modified L1 and L2 genes are necessary for high-yield HPV PsV production .
Cell-surface heparan sulphates are essential for binding and uptake of VLPs of various HPV types (Combita et al., 2001; Drobni et al., 2003; Joyce et al., 1999) as well as for infection by HPV PsVs (Giroglou et al., 2001; Shafti-Keramat et al., 2003) . Heparin, a highly sulphated form of heparan sulphate proteoglycan secreted by mast cells, interferes with HPV pseudoinfection and has been shown IP: 54.70.40.11 On: Thu, 27 Dec 2018 21:12:55 to bind VLPs efficiently (Giroglou et al., 2001; Joyce et al., 1999) . The interaction with heparin requires intact conformation of VLPs (Giroglou et al., 2001; Rommel et al., 2005) . It has been shown that heparin-based ELISAs reduce background reactivity in HPV VLP-based papillomavirus serology, as incorrectly folded VLPs do not bind heparin .
The current standard HPV serology method is VLP ELISA Pagliusi et al., 2006) . A limitation of the ELISA method is that it requires a large amount of serum, as only antibodies against one genotype of HPV can be tested in each well. Therefore, an immunoassay that measures HPV type-specific antibodies to several HPV genotypes simultaneously would be advantageous. Several groups have described high-throughput multiplex HPV serology using VLPs covalently attached to beads (Dias et al., 2005; Opalka et al., 2003) or capsomeres of L1 proteins expressed as glutathione S-transferase (GST) fusion proteins (Waterboer et al., 2005) . The use of GST-L1 proteins in high-throughput multiplex systems is the most efficient method to measure seroreactivity to HPV, as this type of antigen has been developed for a large number of different HPV genotypes, although these antigens are not native and are not extensively validated with clinical samples (Waterboer et al., 2005) .
We wished to establish and validate a high-throughput HPV serology multiplex method based on native antigen. We used heparin-coated beads to bind PsVs for ten different HPV types . Following optimization and establishment of the method, we validated the method using monoclonal antibodies (mAbs), with positive-and negative-control human serum panels and using a prospective cohort study of cervical cancer (Lehtinen et al., 1996) .
RESULTS

PsV production
The production of HPV-38 PsVs followed the guidelines of Buck et al. (2004) in both gene design and production. The other PsVs were produced using plasmids obtained from Dr Chris Buck (National Cancer Institute, Bethesda, MD, USA) according to the same methods. Analysis by transmission electron microscopy (TEM) indicated that HPV-38 PsVs did not differ from previously published HPV PsVs in size or shape (Fig. 1) . The yield and concentrations were also in the same range (Fig. 2 ). From 75 cm 2 flasks with transformed 293TT cells, concentrations of PsV preparations ranged from 30 to 150 ng ml 21 and the general yield was 200-300 mg.
Validation
We tested mAbs against six HPV types with our PsV-Luminex method. These were raised against HPV-6 (6.M48), HPV-11 (11.H3), HPV-16 (16.V5), HPV-18 (18.J4), HPV-31 (31.A6) and HPV-52 (52.A7 and 52.C1) (Christensen et al., 1996a (Christensen et al., , b, 2001 Rizk et al., 2008) . The mAbs were tested at final dilutions of 1 : 500 and 1 : 1500. The mAbs reacted with the PsVs bound to the heparincoated beads in a monospecific manner ( Table 1) .
Analysis of the negative controls with 63 serum samples from children (af Geijersstam et al., 1999) , found that two children were positive for HPV-5 and one child each for HPV-6, -16, -18 and -52 ( Table 2 ). The four children that were seropositive for a mucosal HPV type were all weakly positive, just above the cut-off. Analysis of the serum samples from middle-aged women with up to one lifetime sexual partner showed that none of the women was seropositive for HPV-11 or -52, but for other mucosal types we found modest levels of seropositivity (4 % for HPV-16, 3 % for HPV-6 and 45, and 1 % for . The seroprevalence of the cutaneous HPV types was higher, as expected (11 % for HPV-5 and 13 % for HPV-38) ( Table 2) .
To create HPV-positive serum panels, serum samples with known HPV DNA status (Forslund et al., 2007; Naucler et al., 2004; Silins et al., 2004) or with a history of condylomata acuminata (Forslund et al., 2002) were analysed with the PsV-Luminex method. Compared with samples from Europe (Forslund et al., 2002 (Forslund et al., , 2007 Silins et al., 2004) , samples from Africa (Naucler et al., 2004) had an approximately threefold higher background signal and much lower agreement between HPV DNA and serology status ( Table 3) . Samples from Europeans showed agreement between HPV DNA status and antibody status that was essentially consistent with previous data on the sensitivity of HPV serology (Table 3) .
HPV-58 showed good agreement between DNA and anti-HPV antibody status in both European and African serum samples (Table 3) , although the number of observations was low. The proportion of the antibody-positive individuals out of DNA-negative individuals for most HPV types was generally smaller than the proportion of the antibodypositive individuals out of DNA-positive individuals (Table 3) . Cutaneous types had higher seropositivity in DNA-negative individuals compared with mucosal types (Table 3 ). Among individuals with a self-reported condylomata acuminata history, anti-HPV-6 antibodies were considerably more common than HPV-11 antibodies as expected in this study population. Out of 69 condyloma patient samples, 25 (36 %) had anti-HPV-6 antibodies whilst only four (6 %) had anti-HPV-11 antibodies. Surprisingly, samples from subjects verified to be HPV-45 or -52 DNA-positive in general did not contain antibodies against these types. To exclude the possibility that heparin binding might change the conformation of these PsVs and therefore change the ability for antibody binding, these samples were also studied using standard heparin-free ELISA. Samples that were HPV-45 and -52 DNA-positive but seronegative by the PsV-Luminex method remained seronegative using a standard ELISA with these PsVs (data not shown). The mAbs against HPV-52 tested in the current study had a high specificity and antigenic reactivity against the HPV-52 PsVs. We did observe human serum samples with an antibody response against HPV-45 and HPV-52, but these were mostly from subjects with an HPV DNA-negative status for these types (Table 3) . Quality-control checks of the PsVs by electron microscopy and gel electrophoresis found no sign of lower quality of the HPV-45 or -52 PsVs (Figs 1 and 2) and our failure to validate the HPV-45 and -52 assays using human serum samples therefore remains unexplained.
From a cohort of 18 814 women followed for 23 years, the baseline serum samples of the 71 women who developed cervical cancer during follow-up and 137 matched control women who did not develop cervical cancer (Lehtinen et al., 1996) were analysed by the new PsV-Luminex method. Calculation of antibody units requires linearity of results from titrations, and these samples were therefore also analysed at 1 : 50 and 1 : 150 dilutions. ELISA data from our previous study (Lehtinen et al., 1996) and the Luminex data agreed well for most of the samples (Fig. 3) . Agreement between two methods was substantial (Landis & Koch, 1977) , with k50.77. A cut-off level of 0.58 IU ml 21 [equivalent to 250 median fluorescent intensity (MFI) units at a 1 : 50 dilution] yielded the same total number of positive samples (12 %) as in a previous study with the ELISA method where the cut-off level was 100 absorbance units (Lehtinen et al., 1996) .
The most common HPV seropositivity in the populationbased cohort was for the cutaneous HPV-5, followed by HPV-38 and HPV-6 ( Table 4 ). As expected, HPV-16 seropositivity conferred the strongest risk for future cervical cancer: odds ratio (OR)57.7 [95 % confidence interval (CI)52.6-23.0] (Table 4 ). HPV-31 seropositivity also conferred a strongly elevated cervical cancer risk: 
DISCUSSION
In present study, we established and validated an HPV serology method based on Luminex technology, heparin coating of the beads and PsVs of ten HPV types, produced in mammalian cell lines. We validated the method using mAbs raised against specific HPV types, human serum samples with known or expected HPV DNA status (af Geijersstam et al., 1999; Forslund et al., 2002 Forslund et al., , 2007 Naucler et al., 2004; Silins et al., 2004) and previous HPV-16 ELISA data (Lehtinen et al., 1996) .
The reactivity with neutralizing mAbs indicated an adequate type specificity and antigenic reactivity of our assays, except for HPV-5, -38 and -45 where we did not have access to neutralizing mAbs. The HPV-16 PsV data were in substantial agreement with the standard ELISA data, which is satisfactory considering that the ELISA data on these samples was obtained 15 years ago (Lehtinen et al., 1996) .
Similarly, the specificity evaluation using serum samples from children found similar results to a previous study with a VLP ELISA (af Geijersstam et al., 1999) , where seropositivity for sexually transmitted HPV types was found to be uncommon in children (,2 % seroprevalence) (af Geijersstam et al., 1999) . Both DNA prevalence and seroprevalence of cutaneous HPV types increase from infancy to adolescence (Antonsson et al., 2003; Michael et al., 2008) . Our results are in agreement with this view of the natural history of cutaneous HPV types, as only two children out of 63 had a serology response to the studied cutaneous HPV types. The antibody responses to mucosal HPV types were weak, just around the cut-off. Antibodies against mucosal HPV originating from the mother is a possible explanation, as these children were young (mean age, 1.5 years) and maternal IgG is expected to persist for up to 6 months after birth .
Higher HPV seroprevalences among children have been reported from Africa (5 % of infants positive for HPV-16 antibodies, 14 % for HPV-11 and 11 % for HPV-18) (Marais et al., 2007) . In our study, the African serum samples had a threefold higher background signal with uncoated negative-control beads compared with the European serum samples, which resulted in a poor sensitivity of the serology for analysis of the African samples. The problem with specificity of serology in African samples is well known in general and is usually attributed to a high burden of infections.
The HPV DNA data and serology data from European samples agreed well with previously reported data: about half of the HPV-16 DNA-positive samples were also seropositive (Carter et al., 1996; Dillner et al., 1995) . Among individuals with self-reported condylomata acuminata in Sweden, about 60 % of the condylomas contain HPV-6 DNA and about 10 % contain HPV-11 DNA (Sturegard et al., 2008) . Although we did not have HPV DNA data on the condyloma patients tested in this study, the proportion of HPV-6 and -11 seropositive subjects is therefore in agreement with the expected type distribution of HPV types in condylomas in this population. The expected proportion of seropositive samples compared with DNA-positive samples is around 50 % and in our study this applied to Our results from the prospective cervical cancer study demonstrated an association between later cervical cancer and prevalence of antibody response at baseline to HPV-16 and -31. The results for the other mucosal HPV types and cutaneous HPV types were also as expected. The expected data from the cohort study therefore contribute further to the clinical validation of our assay.
Surprisingly, antibodies against HPV-45 and -52 were not prevalent in serum samples from DNA-positive patients of these HPV types, in spite of the fact that HPV-52 reacted well with neutralizing mAbs. We excluded the possibility that these results were caused by conformational changes induced by binding to heparin, as similar results were obtained in standard ELISAs with these PsVs. We did observe HPV-45 and -52 seropositive individuals among HPV DNA-negative ones, although a larger group of DNAnegative individuals was studied. The reason for the failure to validate the HPV-45 and -52 assays is unknown, but lower immunogenicity, a longer time required for seroconversion, the existence of serological subtypes (variants) or some aspect of the quality of the HPV45 and -52 PsVs that was not measured in our quality-control programme are conceivable explanations. As the problem was the same in standard ELISA, we can conclude that the sensitivity and specificity of the PsV-Luminex serology method is similar to standard HPV ELISA methods based on high-quality VLPs.
In summary, we developed a high-throughput HPV serology method based on native PsVs, validated it and used it in a prospective cervical cancer study. The major drawback of our method is the time and resources required for PsV production, including the design and synthesis of codon-modified L1 and L2 genes. We found the method of Buck et al. (2004) for design of codon-modified L1 and L2 genes and PsV production to work well. Ideally, PsVs of all the major HPV types should be created and used in serology studies in the future. Valid, rapid and simple highthroughput methods for HPV serology against multiple HPV types are necessary for HPV vaccinology, as well as for continued studies towards an understanding of the epidemiology of the different HPV types and their involvement in human diseases.
METHODS
Cell lines. 293TT cells were grown in complete Dulbecco's modified Eagle medium (Invitrogen) containing 10 % heat-inactivated fetal bovine serum (Invitrogen) supplemented with 1 % GlutaMAX (Invitrogen), 1 % non-essential amino acids (Invitrogen) and 400 mg hygromycin B (InvivoGen) ml 21 for maintenance of Tantigen expression.
Plasmids. HPV L1 and L2 expression vectors were kindly provided by Drs Chris Buck and John Schiller (National Cancer Institute, Bethesda, MD, USA). Nucleotide sequences of these plasmids can be found at http://home.ccr.cancer.gov/lco/default.asp. Shell plasmids are bicistronic and contain both L1 and L2 genes. We used p5Shell, p6Shell, p16Shell, p18Shell, p31Shell, p45Shell, p52Shell, p58Shell, p11L1W and p11L2W to generate HPV PsVs. We generated a new plasmid, p38Shell, by cloning modified and chemically synthesized HPV-38 L1 and L2 genes into the p5Shell vector. For the HPV-38 L1 and L2 constructs, the HPV-38 nucleotide sequence (GenBank accession no. U31787) was codon modified using the principles described by Buck et al. (2004) and elaborated at http://home.ccr. cancer.gov/lco/codonmodification.htm. The genes were chemically synthesized by Blue Heron Biotechnologies, confirmed by sequencing and cloned using the restriction enzymes BspEI and PspXI (for L1) and NotI and NheI (for L2) to replace HPV-5 L1 and L2 from the p5Shell vector with HPV-38 genes.
Generation of PsVs. PsVs were generated by transfection of 293TT cells as described elsewhere . Briefly, 7.5610 6 293TT cells were plated 16 h before transfection in 75 cm 2 flasks. Lipofectamine 2000 (Invitrogen) was used for transfection, as directed by the manufacturer, using 85 ml of the lipid reagent and a total of 38 mg plasmid DNA per flask. For the production of 38 mg Shell plasmid was used, and for HPV-11, 19 mg each of p11L1W and p11L2W were transfected. After 6 h, the medium on the transfected cells was replaced. Cells were harvested at approximately 45 h post-transfection. Cells were trypsinized and rinsed with Dulbecco's PBS (DPBS; Invitrogen). Pellets were resuspended at 5610 7 cells ml 21 in DPBS supplemented with an additional 9.5 mM MgCl 2 . Brij 58 and Benzonase (Sigma) were each added to a final concentration 0.5 % and Plasmid-safe ATP-dependent DNase (Epicentre) was added to a concentration of 0.2 %. The mixture was incubated at 37 uC for 16 h to mature the PsVs. The NaCl concentration was adjusted to 850 mM and the mixture was placed on ice for 10 min, then clarified by spinning at 5000 g for 10 min. The supernatant was transferred into a siliconized tube. The pellet was resuspended in 250 ml DPBS supplemented with 0.8 M NaCl to gather more PsVs. Both tubes were centrifuged again and the supernatants were combined in a siliconized tube. material was centrifuged at 255 000 g for 3.5 h at 16 uC and collected by bottom puncture of the tubes. Fractions were inspected for purity on 10 % NuPage Bistris gels (Invitrogen) and then pooled and frozen at 280 uC. Virus particles were adsorbed onto carbon-coated grids, stained with uranyl formate and examined by TEM.
PsV-Luminex method. Luminex COOH beads (Bio-Rad) were treated as recommended by the manufacturer. After the bead activation step, the beads were conjugated with heparin at 0.75 mg ml 21 (Sigma-Aldrich) in sterile water at room temperature for 16 h. A suitable heparin concentration was determined by titration, as was the optimal PsV coating concentration, which was between 0.5 and 2.5 mg ml 21 , depending on the HPV type. (Grabowska et al., 2002) . For the HPV-16 serology results, data were converted to international units (IU) ml 21 , as HPV-16 serology is standardized Pagliusi et al., 2006) .
A cut-off level of 0.58 IU ml 21 (equivalent to 250 MFI at a 1 : 50 dilution) yielded the same total number of positive samples (12 %) as in a previous study with the ELISA method (Lehtinen et al., 1996) . This cut-off was used throughout this study for all HPV types.
The mean coefficient of variation between plates run on the same day was 29 % and between plates run on different days was 37 %.
mAbs, serum samples and study populations. mAbs 6.M48, 11.H3, 16.V5, 18.J4, 31.A6, 52.A7 and 52.C1 were a kind gift from Dr Neil Christensen (Christensen et al., 1996a (Christensen et al., , b, 2001 Rizk et al., 2008) . Validation panels of serum samples came from five previously published studies. Serum samples had been stored at -80 or -20 uC.
Positive-control serum samples with PCR-verified HPV DNA status came from 130 cervical cancer patients from Latvia (Silins et al., 2004) and 124 cervical cancer patients from Mozambique (Naucler et al., 2004) . The positive-control serum panel for the cutaneous types HPV-5 and -38 were from 434 patients with known HPV DNA status in skin samples in a skin cancer study within a Swedish population (Forslund et al., 2007) . Sixty-nine samples from middle-aged Swedish women with self-reported condylomata acuminata history (Forslund et al., 2002) were used as a positive-control serum panel for HPV-6 and -11. A serum panel containing serum from 63 children with a mean age of 1.5 years (af Geijersstam et al., 1999) was analysed as a negative control. Samples from 71 adult women, with a mean age of 43 years and with limited sexual experience (70 women with one lifetime sexual partner and one woman with no lifetime sexual partners) were also analysed as negative controls (Kjellberg et al., 1999) . After the method was established and validated, 208 serum samples from a nested case-control study of cervical cancer (Lehtinen et al., 1996) were analysed. The study population comprised 18 814 women from the Finnish Mobile Clinic study and were followed for up for 23 years (Hakama et al., 1993) . During this time period, 71 eligible cervical cancer cases occurred. Altogether, 137 controls, matched individually for age and municipality, were selected (Hakama et al., 1993) . This study had previously been analysed for antibodies to HPV-16 by a standard ELISA method (Lehtinen et al., 1996) .
Statistics. The relative risks of cervical carcinoma were estimated by conditional logistic regression for matched sets of case-control triplets (one case, two controls) using SAS version 9.2. Agreement between assays beyond the agreement expected by chance was quantified using k statistics, where k5(observed agreement2chance agreement)/(12chance agreement).
